Report of the EULAR Standing Committee for International clinical Studies Including therapeutic Trials (ESCISIT)

Por VAN RIEL, P L C M
Publicado em 2001

To be in remission or not: is that the question?

Por van Riel, P L C M, Fransen, J
Publicado em 2005

Targeted therapies: summary clinical trials working group

Por Weinblatt, M E, van Riel, P L C M
Publicado em 2006

Clinical outcome measures in rheumatoid arthritis

Por van Riel, P. L C M, van Gestel, A. M
Publicado em 2000

Refractory adult onset Still's disease and hypersensitivity to non-steroidal anti-inflammatory drugs and cyclo-oxygenase-2 inhibitors: are biological agents the solution?

Por Aarntzen, E, van Riel, P L C M, Barrera, P
Publicado em 2005

Bone mass in patients with rheumatoid arthritis.

Por Laan, R F, van Riel, P L, van de Putte, L B
Publicado em 1992

Scintigraphic detection of tumour necrosis factor in patients with rheumatoid arthritis

Por Barrera, P, Oyen, W, Boerman, O, van Riel, P L C M
Publicado em 2003

Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: a multicentre, cluster randomised controlled trial

Por Fransen, J, Moens, H, Speyer, I, van Riel, P L C M
Publicado em 2005

Disease assessment in rheumatoid arthritis.

Por Van Riel, P L, Van der Heijde, D M, Van de Putte, L B
Publicado em 1989

Health Assessment Questionnaire modifications: is standardisation needed?

Por Zandbelt, M, Welsing, P, van Gestel, A M, van Riel, P L C M
Publicado em 2001

Development of type 1 diabetes in a patient treated with anti-TNF-α therapy for active rheumatoid arthritis

Por Tack, C. J., Kleijwegt, F. S., Van Riel, P. L. C. M., Roep, B. O.
Publicado em 2009

A double blind comparative study of sulphasalazine and hydroxychloroquine in rheumatoid arthritis: evidence of an earlier effect of sulphasalazine.

Por Nuver-Zwart, I H, van Riel, P L, van de Putte, L B, Gribnau, F W
Publicado em 1989

Early treatment of rheumatoid arthritis: rationale, evidence, and implications

Por VAN DE PUTTE, L B A, VAN GESTEL, A M, VAN RIEL, P L C M
Publicado em 1998

Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis

Por Flendrie, M, Creemers, M, Welsing, P, den Broeder, A A, van Riel, P L C M
Publicado em 2003

Interleukin-6 in relation to other proinflammatory cytokines, chemotactic activity and neutrophil activation in rheumatoid synovial fluid.

Por van Leeuwen, M A, Westra, J, Limburg, P C, van Riel, P L, van Rijswijk, M H
Publicado em 1995

Clinical significance of interleukin-6 measurement in early rheumatoid arthritis: relation with laboratory and clinical variables and radiological progression in a three year prosp...

Por van Leeuwen, M A, Westra, J, Limburg, P C, van Riel, P L, van Rijswijk, M H
Publicado em 1995

Markers of inflammation are negatively correlated with serum leptin in rheumatoid arthritis

Por Popa, C, Netea, M, Radstake, T, van Riel, P L, Barrera, P, van der Meer, J W M
Publicado em 2005

Consensus Dutch Health Assessment Questionnaire

Por Boers, M, Jacobs, J W G, van Vliet Vlieland, T P M, van Riel, P L C M
Publicado em 2007

Rheumatoid arthritis patients and rheumatologists approach the decision to escalate care differently: Results of a maximum difference scaling experiment

Por van Hulst, L.T.C., Kievit, W., van Bommel, R., van Riel, P.L.C.M., Fraenkel, L.
Publicado em 2011

Response criteria for slow acting antirheumatic drugs.

Por van der Heijde, D M, van Riel, P L, van 't Hof, M A, van de Putte, L B
Publicado em 1990